Gilead Sciences
GILD · Biotechnology
$156.04
0.7%Regeneron Pharmaceuticals
REGN · Biotechnology
$805.02
1.7%The short version
- Gilead Sciences is the larger business, with $29.4B of revenue in fiscal 2025 against $14.3B for Regeneron Pharmaceuticals, about 2.1 times as much.
- Gilead Sciences grew revenue faster (2.4%, against 1.0%).
- Gilead Sciences kept more of each dollar of sales as operating profit (34.0% operating margin, against 25.0% operating margin).
- Gilead Sciences turned more of its sales into free cash flow (32.1% FCF margin, against 28.5% FCF margin).
- Gilead Sciences earned a higher return on the capital invested in it (23.0%, against 12.7%).
| Latest fiscal year | GILD · FY25 | REGN · FY25 |
|---|---|---|
| Size | ||
| Market cap | $194.0B | $85.3B |
| Revenue | $29.4B | $14.3B |
| Free cash flow | $9.5B | $4.1B |
| Net income | $8.5B | $4.5B |
| Growth | ||
| Revenue growth | 2.4% | 1.0% |
| 5-year growth | 3.6% | 11.0% |
| Share count change | 0.0% | −5.7% |
| Profitability | ||
| Gross margin | 78.8% | — |
| Operating margin | 34.0% | 25.0% |
| Net margin | 28.9% | 31.4% |
| FCF margin | 32.1% | 28.5% |
| Return on capital | 23.0% | 12.7% |
| Return on equity | 40.5% | 14.9% |
| Balance sheet | ||
| Net debt | $17.3B | −$5.9B |
| Net debt / EBITDA | 1.4x | −1.4x |
| Dividends and buybacks | $5.9B | $3.8B |
| Valuation & quality | ||
| P/E | — | 19.9x |
| Piotroski F-score | 8 | 5 |
FY16
GILD $30.4B
REGN $4.9B
FY17
GILD $26.1B
REGN $5.9B
FY18
GILD $22.1B
REGN $5.1B
FY19
GILD $22.4B
REGN $6.6B
FY20
GILD $24.7B
REGN $8.5B
FY21
GILD $27.3B
REGN $16.1B
FY22
GILD $27.3B
REGN $12.2B
FY23
GILD $27.1B
REGN $13.1B
FY24
GILD $28.8B
REGN $14.2B
FY25
GILD $29.4B
REGN $14.3B
GILD
REGN
FY16
GILD 58.0%
REGN 27.4%
FY17
GILD 54.1%
REGN 35.4%
FY18
GILD 37.1%
REGN 49.3%
FY19
GILD 19.1%
REGN 33.7%
FY20
GILD 16.5%
REGN 42.1%
FY21
GILD 36.3%
REGN 55.7%
FY22
GILD 26.9%
REGN 38.9%
FY23
GILD 28.1%
REGN 30.9%
FY24
GILD 5.8%
REGN 28.1%
FY25
GILD 34.0%
REGN 25.0%
GILD
REGN
FY16
GILD $16.3B
REGN $974M
FY17
GILD $11.3B
REGN $1.0B
FY18
GILD $7.5B
REGN $1.8B
FY19
GILD $8.3B
REGN $2.0B
FY20
GILD $7.5B
REGN $2.0B
FY21
GILD $10.8B
REGN $6.5B
FY22
GILD $8.3B
REGN $4.4B
FY23
GILD $7.4B
REGN $3.9B
FY24
GILD $10.3B
REGN $3.7B
FY25
GILD $9.5B
REGN $4.1B
GILD
REGN
FY16
GILD 46.0%
REGN 29.8%
FY17
GILD 22.7%
REGN 29.4%
FY18
GILD 24.3%
REGN 45.4%
FY19
GILD 20.6%
REGN 26.5%
FY20
GILD 6.3%
REGN 35.2%
FY21
GILD 17.8%
REGN 59.8%
FY22
GILD 14.2%
REGN 25.3%
FY23
GILD 15.5%
REGN 21.5%
FY24
GILD 3.0%
REGN 18.0%
FY25
GILD 23.0%
REGN 12.7%
GILD
REGN
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.